75 results
Page 2 of 4
S-4/A
04wrwf1n58pv0gj9
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
425
cn5foe qe8tzh8
9 Jun 23
Business combination disclosure
4:31pm
425
8ky0 t8jmuiulwuot
17 May 23
Business combination disclosure
4:54pm
10-Q
fs0 j1zl3
15 May 23
Quarterly report
4:30pm
S-4
EX-10.9
4hu4idl6ty9vp51bz
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
1rbnsn6z
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.11
cfgwvzi1 1pcp46lp
11 May 23
Registration of securities issued in business combination transactions
9:09am
425
se57y8ram37sxu won
18 Apr 23
Business combination disclosure
5:12pm
6-K
EX-99.3
29cpi0
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.3
slv nbtu5
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.2
6l80t0m
2 Jun 22
Notice of Annual General Meeting of Shareholders
5:00pm
6-K
EX-99.3
dan8l0mpankvhu bdv
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
424B5
j0rcvc
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.1
goaeoh4
5 Oct 21
VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
4:17pm
6-K
EX-99.2
2af6 al8ik
2 Sep 21
Notice of Annual General Meeting of Shareholders
7:20am
6-K
EX-99.1
55fgfayqsoxcbspdqq
8 Jul 21
VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors
4:05pm
POS AM
34bpry
19 Apr 21
Prospectus update (post-effective amendment)
5:17pm
424B8
gi2aa voxev0
19 Apr 21
Prospectus unintentially filed late
5:06pm
424B5
yd6fod9v43 u5fyzmp8
12 Apr 21
Prospectus supplement for primary offering
9:07am